SLRN240920P5000
- 0.55
- +0.06+12.24%
Acelyrin Newsroom
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
Express News | ACELYRIN Inc : Morgan Stanley Cuts Target Price to $6 From $13
ACELYRIN Is Maintained at Equal-Weight by Morgan Stanley
ACELYRIN Price Target Cut to $6.00/Share From $13.00 by Morgan Stanley
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $6
ACELYRIN, INC.: Hold Rating Maintained Amid Strategic Pipeline Shift and Extended Cash Runway
Express News | HC Wainwright & Co. Downgrades Acelyrin to Neutral, Lowers Price Target to $6
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
ACELYRIN Is Maintained at Overweight by Piper Sandler
Express News | Piper Sandler Maintains Overweight on Acelyrin, Lowers Price Target to $20
Acelyrin Analyst Ratings
Acelyrin Shares Slide on Layoffs, Portfolio Refocus
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Express News | ACELYRIN Inc Shares Down 8.8% Premarket After H.c. Wainwright Cuts to Neutral
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
Express News | ACELYRIN Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results
Piper Sandler Keeps Their Buy Rating on ACELYRIN, INC. (SLRN)
ACELYRIN, INC. Maintains Hold Rating Amidst Mixed Clinical Results and Competitive Market Challenges